FASANO, Serena
 Distribuzione geografica
Continente #
EU - Europa 2.424
AS - Asia 1.074
NA - Nord America 1.041
SA - Sud America 195
Continente sconosciuto - Info sul continente non disponibili 73
AF - Africa 7
OC - Oceania 1
Totale 4.815
Nazione #
RU - Federazione Russa 1.727
US - Stati Uniti d'America 1.018
IE - Irlanda 313
SG - Singapore 285
HK - Hong Kong 269
CN - Cina 226
BR - Brasile 153
VN - Vietnam 120
IT - Italia 119
GB - Regno Unito 78
KR - Corea 60
DE - Germania 34
IN - India 34
FR - Francia 33
GR - Grecia 27
SE - Svezia 26
UA - Ucraina 22
AR - Argentina 18
JP - Giappone 16
BD - Bangladesh 13
TR - Turchia 12
ES - Italia 10
PL - Polonia 10
MX - Messico 9
EC - Ecuador 7
FI - Finlandia 7
CA - Canada 6
ID - Indonesia 5
IQ - Iraq 5
NL - Olanda 5
VE - Venezuela 5
CO - Colombia 4
MY - Malesia 4
PK - Pakistan 4
PT - Portogallo 4
AT - Austria 3
PA - Panama 3
PY - Paraguay 3
AZ - Azerbaigian 2
BE - Belgio 2
CL - Cile 2
CZ - Repubblica Ceca 2
IL - Israele 2
JM - Giamaica 2
KG - Kirghizistan 2
KZ - Kazakistan 2
SA - Arabia Saudita 2
TN - Tunisia 2
UZ - Uzbekistan 2
ZA - Sudafrica 2
AE - Emirati Arabi Uniti 1
AL - Albania 1
AM - Armenia 1
AU - Australia 1
BH - Bahrain 1
CR - Costa Rica 1
EU - Europa 1
GL - Groenlandia 1
JO - Giordania 1
LK - Sri Lanka 1
MA - Marocco 1
NG - Nigeria 1
NI - Nicaragua 1
NP - Nepal 1
PE - Perù 1
PS - Palestinian Territory 1
RO - Romania 1
SN - Senegal 1
SR - Suriname 1
SY - Repubblica araba siriana 1
TW - Taiwan 1
UY - Uruguay 1
Totale 4.743
Città #
Moscow 597
Dublin 313
Hong Kong 264
Santa Clara 192
San Jose 154
Singapore 106
Chandler 96
Jacksonville 69
Seoul 58
Ashburn 53
Ho Chi Minh City 43
Beijing 40
Hefei 36
Princeton 33
Hanoi 32
Roxbury 32
Medford 24
Bremen 20
Caserta 15
Bengaluru 13
Los Angeles 13
The Dalles 13
Cambridge 11
Des Moines 11
Dallas 10
New York 10
São Paulo 10
Da Nang 9
Haiphong 8
Jinan 8
Nanjing 8
Pamplona 8
Tokyo 8
Warsaw 8
Wilmington 8
Boardman 7
Ann Arbor 6
Chennai 6
Guangzhou 6
Naples 6
Rio de Janeiro 6
Dhaka 5
Marseille 5
Buenos Aires 4
Caracas 4
Guayaquil 4
Mexico City 4
Milan 4
Napoli 4
Sant'Angelo in Formis 4
Shanghai 4
Villa Literno 4
Atlanta 3
Belo Horizonte 3
Biên Hòa 3
Brooklyn 3
Campinas 3
Campo Grande 3
Changsha 3
Chicago 3
Columbus 3
Council Bluffs 3
Falkenstein 3
Francavilla Fontana 3
Goiânia 3
Hyderabad 3
Marília 3
Mumbai 3
Phoenix 3
Quảng Ngãi 3
Rome 3
San Francisco 3
Shenyang 3
Taviano 3
Almaty 2
Aparecida de Goiânia 2
Baku 2
Betim 2
Bishkek 2
Boston 2
Brussels 2
Bắc Ninh 2
Charleston 2
Essex 2
Frankfurt am Main 2
Guarulhos 2
Gwangju 2
Hebei 2
Hillsboro 2
Huế 2
Hải Dương 2
Jiaxing 2
Johannesburg 2
Juiz de Fora 2
Kraków 2
Krasnodar 2
Kuala Lumpur 2
Lanzhou 2
Lappeenranta 2
Lisbon 2
Totale 2.534
Nome #
Biologic treatments for idiopathic inflammatory myopathies 192
Longterm Hydroxychloroquine Therapy and Low-dose Aspirin May Have an Additive Effectiveness in the Primary Prevention of Cardiovascular Events in Patients with Systemic Lupus Erythematosus 147
Low-dose aspirin as primary prophylaxis for cardiovascular events in systemic lupus erythematosus: A long-term retrospective cohort study 142
Cardiac involvement in undifferentiated connective tissue disease at risk for systemic sclerosis (otherwise referred to as very early-early systemic sclerosis): a TDI study 141
Anifrolumab in Refractory Systemic Lupus Erythematosus: A Real-World, Multicenter Study 128
Durable renal response and safety with add-on belimumab in patients with lupus nephritis in real-life setting (BeRLiSS-LN). Results from a large, nationwide, multicentric cohort 128
Low-dose aspirin as primary prophylaxis for cardiovascular events in rheumatoid arthritis: an Italian multicentre retrospective study 125
Influence of hydroxychloroquine blood levels on adhesion molecules associated with endothelial dysfunction in patients with systemic lupus erythematosus 121
Precision medicine in systemic lupus erythematosus 121
Health status and concomitant prescription of immunosuppressants are risk factors for hydroxychloroquine non-adherence in systemic lupus patients with prolonged inactive disease. 121
Early and Late Response and Glucocorticoid-Sparing Effect of Belimumab in Patients with Systemic Lupus Erythematosus with Joint and Skin Manifestations: Results from the Belimumab in Real Life Setting Study—Joint and Skin (BeRLiSS-JS) 120
Low mortality rate in Italian rheumatoid arthritis patients from a tertiary center: Putative implication of a low anti-carbamylated protein antibodies prevalence 118
Incidence of COVID-19 in an Italian cohort of patients with systemic lupus erythematosus: an observational survey 118
Biomarker panels may be superior over single molecules in prediction of renal flares in systemic lupus erythematosus: an exploratory study 115
The incidence of cardiovascular events in Italian patients with systemic lupus erythematosus is lower than in North European and American cohorts: Implication of disease-associated and traditional risk factors as emerged by a 16-year retrospective GIRRCS study 114
Prevalence and factors associated with glucocorticoids (GC) use in systemic sclerosis (SSc): a systematic review and meta-analysis of cohort studies and registries 113
Clinical features of patients with systemic lupus erythematosus according to health-related quality of life, entity of pain, fatigue and depression: a cluster analysis 113
ILC3 in Axial Spondyloarthritis: the Gut Angle 113
"What is fuelling the immune response in systemic lupus erythematosus?" Evaluating the key metabolites driving plasmablast differentiation 112
Autoimmune gastrointestinal complications in patients with systemic lupus erythematosus: case series and literature review 110
Current pharmacological treatment of idiopathic inflammatory myopathies 109
Microbiome Changes in Connective Tissue Diseases and Vasculitis: Focus on Metabolism and Inflammation 106
Bruton's Tyrosine Kinase Inhibitors: A New Therapeutic Target for the Treatment of SLE? 106
Mortality in Italian patients with rheumatoid arthritis: Evidence for a low mortality rate from cancer and infections in patients followed up at a tertiary center 106
Early disease and low baseline damage predict response to belimumab in patients with systemic lupus erythematosus 105
Hydroxychloroquine daily dose, hydroxychloroquine blood levels and the risk of flares in patients with systemic lupus erythematosus 103
Rituximab in the treatment of inflammatory myopathies: a review 100
Lung involvement in stable undifferentiated connective tissue diseases: a rheumatology perspective 99
Pathogenesis of primary Sjögren's syndrome beyond B lymphocytes 97
Systematic review and meta-analysis of cardiovascular risk in rheumatological disease: Symptomatic and non-symptomatic events in rheumatoid arthritis and systemic lupus erythematosus 95
Prolonged remission is associated with a reduced risk of cardiovascular disease in patients with systemic lupus erythematosus: a GIRRCS (Gruppo Italiano di Ricerca in Reumatologia Clinica e Sperimentale) study 90
Subclinical Pancreatitis as Onset of Systemic Lupus Erythematosus: Case Report and Review of the Literature 90
Undifferentiated connective tissue disease at risk of systemic sclerosis: A weighted score to identify patients who will evolve 88
Which patients with systemic lupus erythematosus in remission can withdraw low dose steroids? Results from a single inception cohort study 86
Primary prevention of cardiovascular disease in patients with systemic lupus erythematosus: case series and literature review 85
Present and novel biologic drugs in primary Sjogren's syndrome 85
Thrombocytopenia in the Antiphospholipid Syndrome 83
Risk factors of flare in patients with systemic lupus erythematosus after glucocorticoids withdrawal. A systematic review and meta-analysis 80
The association between duration of remission, fatigue, depression and health-related quality of life in Italian patients with systemic lupus erythematosus 79
Revised European Scleroderma Trials and Research Group Activity Index is the best predictor of short-term severity accrual 77
Systemic lupus erythematosus and the role of the GP 73
Tailoring the treatment of inflammatory rheumatic diseases by a better stratification and characterization of the clinical patient heterogeneity. Findings from a systematic literature review and experts' consensus 72
Role of the IL-23/IL-17 Pathway in Rheumatic Diseases: An Overview 72
Vasodilators and low-dose acetylsalicylic acid are associated with a lower incidence of distinct primary myocardial disease manifestations in systemic sclerosis: Results of the DeSScipher inception cohort study 71
The role of aspirin in the primary prevention of accelerated atherosclerosis in systemic autoimmune rheumatic diseases 71
Recognition and management of systemic lupus erythematosus 58
Potential involvement of IL-40 in kidney disease associated to systemic lupus erythematosus 10
Incidence and prevalence of systemic lupus erythematosus across Italian referral centers and its clinical burden in terms of disease severity, treatment and hospitalization: The ESCULAPIO study 7
Totale 4.815
Categoria #
all - tutte 18.212
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 18.212


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022188 0 0 0 3 82 0 9 4 10 3 12 65
2022/2023485 39 3 20 14 50 29 0 23 281 1 13 12
2023/2024191 16 17 13 15 80 6 0 1 1 1 5 36
2024/2025749 1 20 4 13 99 94 91 106 63 167 65 26
2025/20262.815 91 126 146 124 257 1.594 142 61 106 64 49 55
2026/202742 16 26 0 0 0 0 0 0 0 0 0 0
Totale 4.815